Dosage and administration
Apply liberally 15 minutes prior to sun exposure to face, neck and areas exposed to the sun. Re-apply after swimming, sweating or after 2 hours.
Apply liberally 15 minutes prior to sun exposure to face, neck and areas exposed to the sun. Re-apply after swimming, sweating or after 2 hours.
HBS Code (Labeler): FP15501-50.1
Distributor: Derma Faith
Human OTC Drug
Avobenzone 3.0%
Homosalate 10.0%
Octisalate 5.0%
Octocrylene 2.0%
Oxybenzone 6.0%
________________________________________________________
sheltered
broad spectrum
spf 55 sunscreen
derma faith
50 ml/1.7 fl oz
sheltered
broad spectrum
spf 55 sunscreen
Apply liberally 15 minutes prior to sun exposure to face, neck and areas exposed to the sun. Re-apply after swimming, sweating or after 2 hours.
For external use only. UV exposure from the sun increases your risk of skin cancer and early skin aging. To reduce risk, limit time in the sun, wear protective clothing and use a broad spectrum sunscreen of SPF15 of higher.
When using this product keep out of eyes. Rinse with water to remove. If rash occurs discontinue use.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center immediately.
Derma Faith, LLC
5701 W. Slaughter Lane
A130 #337
Austin, TX 78749
Made in the U.S.A.
www.dermafaith.com
M050829
This extra care sunscreen features our patented Polargel® UV SPF boosting technology that enables improved sunscreen performance with lower sunscreen actives. Formulated with antioxidants to help fight free radicals, this non-greasy formulation provides broad-spectrum sun protection without feeling thick or oily.
Active ingredients:
Avobenzone 3.0%
Homosalate 10.0%
Octisalate 5.0%
Octocrylene 2.0%
Oxybenzone 6.0%
Water, Butylene Glycol, PEG-8, Polyethylene, Dimethicone, Silica, Picea Abies Wood Extract, Sodium Ascorbyl Phosphate, Retinyl Palmitate, Tocopherol, Tocopheryl Acetate, Titanium Dioxide, Aloe Barbadensis Leaf Juice, Bentonite, Methyl Glucose Sesquistearate, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Polyacrylate, Kaolin, Ethylhexylglycerin, Disodium EDTA, Sodium Hydroxide, Chlorphenesin, Phenoxyethanol
________________________________________________________
150831
AMCOL Health & Beauty Solutions, Inc. DBA
301 Laser Lane Lafayette, LA 70507 |
www.amcolhpc.com
lauren.haase@amcol.com
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68634-050-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-7a3b-f424-e053-dadaa90a57ce | Sheltered Broad Spectrum Sunscreen SPF 55 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68634-050-01 | Sheltered Broad Spectrum SPF 55 Sunscreen | 1 in 1 CARTON | LIQUID | 1 | 1 | |
| 68634-050-01 | Sheltered Broad Spectrum SPF 55 Sunscreen | 50 mL in 1 BOTTLE | LIQUID | 50 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 68634-050 | SHELTERED BROAD SPECTRUM SPF 55 SUNSCREEN (HOMOSALATE, OXYBENZONE, OCTISALATE, AVOBENZONE, OCTOCRYLENE) LIQUID [AMCOL HEALTH & BEAUTY SOLUTIONS, INC. DBA] | 1 | Legacy NDC, 2 package rows | 20150909_c8d1be79-a585-4e04-ade2-4ee6d8e962a6.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| avobenzone | ACTIVE INGREDIENT | G63QQF2NOX | 1 | |
| homosalate | ACTIVE INGREDIENT | V06SV4M95S | 1 | |
| octisalate | ACTIVE INGREDIENT | 4X49Y0596W | 1 | |
| octocrylene | ACTIVE INGREDIENT | 5A68WGF6WM | 1 | |
| oxybenzone | ACTIVE INGREDIENT | 95OOS7VE0Y | 1 | |
| avobenzone | ACTIVE MOIETY | G63QQF2NOX | 1 | |
| homosalate | ACTIVE MOIETY | V06SV4M95S | 1 | |
| octisalate | ACTIVE MOIETY | 4X49Y0596W | 1 | |
| octocrylene | ACTIVE MOIETY | 5A68WGF6WM | 1 | |
| oxybenzone | ACTIVE MOIETY | 95OOS7VE0Y | 1 | |
| .alpha.-tocopherol acetate, DL- | INACTIVE INGREDIENT | WR1WPI7EW8 | 1 | |
| aloe vera leaf | INACTIVE INGREDIENT | ZY81Z83H0X | 1 | |
| bentonite | INACTIVE INGREDIENT | A3N5ZCN45C | 1 | |
| butylene glycol | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| carbomer copolymer type A | INACTIVE INGREDIENT | 71DD5V995L | 1 | |
| chlorphenesin | INACTIVE INGREDIENT | I670DAL4SZ | 1 | |
| dimethicone | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| edetate disodium | INACTIVE INGREDIENT | 7FLD91C86K | 1 | |
| ethylhexylglycerin | INACTIVE INGREDIENT | 147D247K3P | 1 | |
| high density polyethylene | INACTIVE INGREDIENT | UG00KM4WR7 | 1 | |
| kaolin | INACTIVE INGREDIENT | 24H4NWX5CO | 1 | |
| phenoxyethanol | INACTIVE INGREDIENT | HIE492ZZ3T | 1 | |
| picea abies wood | INACTIVE INGREDIENT | 72GZ8K8996 | 1 | |
| polyethylene glycol 400 | INACTIVE INGREDIENT | B697894SGQ | 1 | |
| silicon dioxide | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| sodium ascorbyl phosphate | INACTIVE INGREDIENT | 836SJG51DR | 1 | |
| sodium hydroxide | INACTIVE INGREDIENT | 55X04QC32I | 1 | |
| sodium polyacrylate (8000 mw) | INACTIVE INGREDIENT | 285CYO341L | 1 | |
| titanium dioxide | INACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| tocopherol | INACTIVE INGREDIENT | R0ZB2556P8 | 1 | |
| vitamin a palmitate | INACTIVE INGREDIENT | 1D1K0N0VVC | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68634-050 | 68634-050-01 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| high density polyethylene | HIGH DENSITY POLYETHYLENE | UG00KM4WR7 | JELLY / VAGINAL | 42.6 %w/w | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / SUBCUTANEOUS | ADJ PH | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SUPPOSITORY / VAGINAL | NA | ||
| phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL, FOAM / TOPICAL | 72 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SUSPENSION / SOFT TISSUE | 1 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SOLUTION / INTRAMUSCULAR | 4 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | CREAM / VAGINAL | 3 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | POWDER / RESPIRATORY (INHALATION) | ADJ PH | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, FILM COATED / ORAL | 4 mg | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | CREAM / TOPICAL | 10 %w/w | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | DROPS / AURICULAR (OTIC) | 0.05 %w/w | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRADERMAL | ADJ PH | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | TABLET, FILM COATED / ORAL | 20 mg | ||
| bentonite | BENTONITE | A3N5ZCN45C | SYSTEM / TRANSDERMAL | 9.86 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBCUTANEOUS | 1 %w/v | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | ELIXIR / ORAL | ADJ PH | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | GEL / TOPICAL | 0.06 %w/w | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | INJECTION, SOLUTION / INTRAMUSCULAR | 20.3 %w/v | ||
| tocopherol | TOCOPHEROL | R0ZB2556P8 | INJECTION, EMULSION / INTRAVENOUS | 0.02 %w/v | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER, FOR SUSPENSION / ORAL | 297 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | TABLET, DELAYED RELEASE / ORAL | 4 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION/ DROPS / OPHTHALMIC | ADJ PH | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | OINTMENT / TOPICAL | 1950 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION/ DROPS / OPHTHALMIC | ADJ PH | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / DENTAL | 19 %w/w | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBMUCOSAL | ADJ PH | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / INTRAVENOUS | 0.05 %w/v | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | INJECTION / INTRAMUSCULAR | 406 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / ORAL | 9120 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION, CONCENTRATE / INTRAVENOUS | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / PERINEURAL | ADJ PH | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE / ORAL | 254 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED / ORAL | 17 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | EMULSION / TOPICAL | 0.2 %w/w | ||
| kaolin | KAOLIN | 24H4NWX5CO | SYSTEM / TOPICAL | 420 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | EMULSION / ORAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRABURSAL | ADJ PH | ||
| kaolin | KAOLIN | 24H4NWX5CO | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 234 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAVASCULAR | ADJ PH | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | SOLUTION / OPHTHALMIC | 46 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / SUBMUCOSAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | FILM, EXTENDED RELEASE / TRANSDERMAL | 0.85 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / RESPIRATORY (INHALATION) | 8 %w/v | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED / ORAL | 166 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | POWDER, FOR SOLUTION / ORAL | ADJ PH | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | DROPS / OPHTHALMIC | 0.05 %w/v | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | TABLET, EXTENDED RELEASE / ORAL | 60 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRATHECAL | ADJ PH | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE / ORAL | 1190 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / AURICULAR (OTIC) | ADJ PH | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 42 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / OPHTHALMIC | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / TOPICAL | 39 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | SOLUTION / ORAL | 336 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | TABLET, COATED / ORAL | NA | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SHAMPOO, SUSPENSION / TOPICAL | 1 %w/w | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / ORAL | 432 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAMUSCULAR | 176 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 8cc522b4-c4f9-40f6-b24c-f58ea9eb8b0c | c8d1be79-a585-4e04-ade2-4ee6d8e962a6 | 2015-08-31 | Warnings | 8cc522b4-c4f9-40f6-b24c-f58ea9eb8b0c c8d1be79-a585-4e04-ade2-4ee6d8e962a6 |
Adverse event summaries are temporarily unavailable. Other product information remains available.